Data as of 11:22am ET
| -0.03 / -3.43%|
DARA BioSciences, Inc. is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products. The company's product portfolio includes Soltamox, Gelclair, Bionect and KRN5500. It holds exclusive U.S. marketing rights to Soltamox (tamoxifen citrate) oral solution, the only liquid form of tamoxifen, used for the treatment and prevention of breast cancer. Soltamox offers a choice to patients who prefer or need a liquid form of tamoxifen. Gelclair is an alcohol-free bioadherent oral rinse gel for rapid and effective relief of pain associated with oral mucositis caused by chemotherapy and radiation treatment. The company markets Bionect, a topical treatment for skin irritation and burns associated with radiation therapy, in U.S. oncology/radiology markets. It also markets KRN5500, currently in Phase 2 for the treatment of chronic, treatment refractory, chemotherapy induced peripheral neuropathy. DARA BioSciences was founded by Steven Gorlin on June 22, 2002 and is headquartered in Raleigh, NC.
|David J. Drutz||Executive Chairman & Chief Medical Officer|
|Christopher G. Clement||President, Chief Executive Officer & Director|
|David L. Tousley||Chief Financial Officer|
|Michael Radomsky||Vice President-Technical Operations|
|David Benharris||VP-Sales, Marketing & Business Development|